Book

Pain Killer: An Empire of Deceit and the Origin of America's Opioid Epidemic

by Barry Meier

📖 Overview

Pain Killer chronicles the rise of OxyContin and the beginnings of America's opioid crisis through investigative reporting and extensive research. Author Barry Meier, a former New York Times reporter, traces the development and aggressive marketing of the powerful painkiller by Purdue Pharma in the 1990s. The narrative follows key figures including pharmaceutical executives, sales representatives, doctors, and patients caught in the early wave of opioid addiction. Meier documents internal company decisions, regulatory oversight, and the mounting evidence of abuse that emerged as OxyContin prescriptions spread across the country. Medical professionals and law enforcement officials share their front-line observations as they began recognizing patterns of addiction in their communities. The book includes accounts from Appalachian regions that were among the first to experience widespread impacts. The work stands as both a business investigation and a public health warning, examining how corporate practices and healthcare policies can intersect with devastating social consequences. Through this pharmaceutical case study, Meier raises questions about medical ethics, regulatory responsibility, and the balance between pain treatment and addiction risk.

👀 Reviews

Readers describe this as a detailed investigation into Purdue Pharma's role in the opioid crisis, with extensive reporting on internal company documents and legal cases. Readers appreciated: - Clear timeline of how OxyContin was developed and marketed - Profiles of key players and whistleblowers - Documentation of early warnings that were ignored - Straightforward writing style that explains complex topics Common criticisms: - Too much focus on legal proceedings - Some sections feel repetitive - Limited coverage of more recent developments - Would benefit from more patient perspectives Ratings: Goodreads: 4.0/5 (1,100+ ratings) Amazon: 4.4/5 (300+ ratings) Representative review: "Meticulous research into how one company's deceptive practices fueled an epidemic. Sometimes gets bogged down in courtroom details but tells an important story." - Goodreads reviewer Several readers noted the book works well as an introduction to understanding the origins of the opioid crisis but recommend supplementing with more current sources.

📚 Similar books

Empire of Pain by Patrick Radden Keefe Chronicles the Sackler family's role in developing OxyContin and their responsibility in the opioid crisis through three generations of power, greed, and denial.

Dopesick by Beth Macy Traces the opioid crisis from its origins in pharmaceutical marketing to its devastating impact on rural communities in Appalachia.

Bad Blood by John Carreyrou Exposes the fraud and deception behind Theranos, revealing how corporate ambition and Silicon Valley culture enabled a massive healthcare scandal.

American Overdose by Chris McGreal Documents the convergence of pharmaceutical companies, doctors, regulators, and policymakers that led to America's opioid epidemic.

Death in Mud Lick by Eric Eyre Details a small-town pharmacist's investigation into the flood of pain pills in West Virginia and the corporate forces behind the distribution.

🤔 Interesting facts

🔍 Author Barry Meier was the first journalist to spotlight OxyContin's addictive properties in a major newspaper, breaking the story in The New York Times in 2001. 💊 The book reveals how Purdue Pharma tested OxyContin on terminal cancer patients but marketed it broadly for chronic pain, despite knowing its addictive potential. 📊 Sales of OxyContin grew from $48 million in 1996 to nearly $1.1 billion in 2000, marking one of the fastest-growing pharmaceutical products in history. ⚖️ The Sackler family, owners of Purdue Pharma, were personally fined $6 billion in 2022 for their role in the opioid crisis, decades after the events described in the book. 🗞️ "Pain Killer" was originally published in 2003 but was substantially updated and rereleased in 2018 to include new developments in the opioid epidemic and subsequent legal battles.